No Data
No Data
Weiguang Biotech: 2024 Semi-Annual Report Summary
Weiguang Biotech: 2024 Semi-Annual Report
Shen Zhen Weiguang Biological Products (002880.SZ): Net income in the first half of the year was 0.1099 billion yuan, a year-on-year increase of 8.75%.
On August 27, Weiguang Biological Products (002880.SZ) announced its semi-annual report for 2024, with a half-year revenue of 0.523 billion yuan, a year-on-year increase of 14.38%; net income attributable to shareholders of the listed company was 0.1099 billion yuan, a year-on-year increase of 8.75%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.108 billion yuan, a year-on-year increase of 8.34%; and the basic earnings per share was 0.4844 yuan.
Shen Zhen Weiguang Biological Products (002880.SZ) released its half-year performance with a net income of 0.11 billion yuan, a year-on-year growth of 8.75%.
Shen Zhen WeiGuang Biological Products (002880.SZ) released its semi-annual report for 2024, with revenue of 0.523 billion yuan, a year-on-year...
Express News | Shen Zhen WeiGuang Biological Products: The company's deputy general manager, Xu Qiang, retired and left his post.
Shen Zhen Weiguang Biological Products (002880): The pioneer of differentiated blood products in China and a rising star in global platformized biomedical industry.
The main supporter of Weiguang biologicals, founded in 1985, has always focused on the field of blood products and has become a domestic leader with high plasma utilization rate, complete product types, and strong R&D capabilities.
No Data
No Data